CN108514568A - The preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur - Google Patents

The preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur Download PDF

Info

Publication number
CN108514568A
CN108514568A CN201810458324.8A CN201810458324A CN108514568A CN 108514568 A CN108514568 A CN 108514568A CN 201810458324 A CN201810458324 A CN 201810458324A CN 108514568 A CN108514568 A CN 108514568A
Authority
CN
China
Prior art keywords
component
achene
siberian cocklebur
rheumatoid arthritis
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810458324.8A
Other languages
Chinese (zh)
Inventor
姜海
杨柳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heilongjiang University of Chinese Medicine
Original Assignee
Heilongjiang University of Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heilongjiang University of Chinese Medicine filed Critical Heilongjiang University of Chinese Medicine
Priority to CN201810458324.8A priority Critical patent/CN108514568A/en
Publication of CN108514568A publication Critical patent/CN108514568A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/35Extraction with lipophilic solvents, e.g. Hexane or petrol ether
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/39Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the preparation method of thiazides compounds in the achene of Siberian cocklebur and its medical usages, the present invention, which screens to have obtained in cocklebur fruit ethanol extract to have, prevents and/or treats rheumatism, the active component of rheumatoid arthritis, the wherein ethyl acetate component of 50 90% ethanol extract of the achene of Siberian cocklebur, n-butanol component, with significant rheumatism, the therapeutic effect of rheumatoid arthritis, the n-butanol component of 50 90% ethanol extract of the achene of Siberian cocklebur is isolated and purified, 11 particular compounds are obtained, the compound shows the effect of the apparent RAFLS cell Proliferations for inhibiting TNF α inductions, it is wherein especially the most apparent with xanthiside effects, it is suitable for rheumatism, the prevention and treatment of rheumatoid arthritis.

Description

The preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur
Technical field
The invention belongs to drug fields, are specifically related to a kind of medicine prevented and/or treat rheumatism, rheumatoid arthritis Compositions and its preparation method and application, i.e., the preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur.
Background technology
Rheumatism, rheumatoid arthritis (Rheumatoid arthritis, RA) are mainly carried out with synovitis and joint Property destroy be main clinical manifestation chronic auto-immune disease, early stage joint part present red and swollen heat pain, it is serious to make At the dysfunction in joint, the strong and deformation that late period can cause joint different degrees of has very high disability rate, specifically Pathogenesis is still unclear at present.The treatment of rheumatism and rheumatoid arthritis is directed in addition to physical exercise and function at present Nursing generally uses non-steroidal anti-inflammatory drugs, glucocorticoid, immunosuppressor etc. to control symptom, mitigate patient suffering, but non- Non-steroidal anti-inflammatory drug will increase cardiovascular risk, cause the side effects such as injury of gastrointestinal tract, lesions of liver and kidney, and glucocorticoid The serious side effects such as central obesity, half a month face, caput femoris necrosis can then be led to, there is also gastrointestinal tract damages for immunosuppressor The serious side effects such as wound, alopecia, bone marrow suppression, Neuroleptic Leukocytopenia, liver renal toxicity, the serious pair present in the above drug Effect limits their applications when rheumatism and rheumatoid are treated.
The achene of Siberian cocklebur also known as azure water, are the drying and ripening of composite family cocklebur Siberian cocklebur (Xanthium sibiricum) Fruit with involucre is distributed on Hebei, Liaoning, Heilungkiang, the Jilin Inner Mongol and other places, is common Chinese herbal medicine, has and dissipate Wind, dehumidifying, sensible effect, are usually used in the treatment of the diseases such as flu, arthralgia pain due to rheumatism, rubella itch.Come from《Prescriptions for Succouring the Sick》It is grey The ears or side handles of a utensil dissipate, and are exactly for rhinitis chronic, the classics recipe of nasosinusitis and allergic rhinitis.
Chinese medicine think rheumatism, rheumatoid arthritis mainly with cold, heat, the stasis of blood, it is wet, empty based on, achene of Siberian cocklebur relieve heat dehumidifies Effect makes it that can be possible to the treatment suitable for rheumatism, rheumatoid arthritis from theory of traditional Chinese medical science angle, is reported if explaining Jianping It can be used for the treatment of rheumatoid arthritis using achene of Siberian cocklebur external application, but chemical composition contained by the achene of Siberian cocklebur is extremely complex, including Volatile oil, aliphatic acid, glycoside, phenolic acid class, thiazine diketone class, sequiterpene, anthraquinone, flavones, alkaloid etc., variety classes ingredient Therapeutic effect it is different so that the achene of Siberian cocklebur and its crude extract for rheumatism, the therapeutic effect of rheumatoid arthritis and are paid no attention to Think, and the active component of achene of Siberian cocklebur antirheumatic, rheumatoid arthritis has not yet to see report.
The present invention is dedicated to screening in the determining achene of Siberian cocklebur for wind on the basis of country actively pushes forward original new drug research and development Wet, rheumatoid arthritis has the extract or particular compound of therapeutic effect, makes every effort to provide a kind of therapeutic effect excellent The medicine composition of rheumatism, rheumatoid arthritis.
Invention content
The present invention provides a kind of prevention and/or treatment rheumatism, the pharmaceutical composition of rheumatoid arthritis and its preparations Method and purposes.
On the one hand, preventing and/or treat rheumatism, the pharmaceutical composition of rheumatoid arthritis the present invention provides a kind of, It is characterized in that described pharmaceutical composition is with the ethyl acetate component of cocklebur fruit ethanol extract or n-butanol component or its mixing Object is active constituent.
Preferably, the cocklebur fruit ethanol extract is achene of Siberian cocklebur 50-90% ethanol extracts, it is furthermore preferred that described grey Ears or side handles of a utensil ethanol extract is achene of Siberian cocklebur 60-80% ethanol extracts;The most preferred cocklebur fruit ethanol extract is the achene of Siberian cocklebur 70% ethanol extract.
Preferably, the prevention and/or treatment rheumatism, the pharmaceutical composition of rheumatoid arthritis, with the achene of Siberian cocklebur 70% The n-butanol group of ethanol extract is divided into active constituent, includes in the n-butanol component of 70% ethanol extract of the achene of Siberian cocklebur Compound is one or more as follows:
(1)7-[(β-D-apiofuranosyl-(1→6)-β-D-glucopyranosyl)oxymethy]-8,8- dimethyl-4,8-dihydrobenzo[1,4]thiazine-3,5-dione;
(2)3-[(2'-hydroxyacetic acid)amino]-1,1-dimethyl-6-hydroxymethyl-2- sulfhydryl-cyclohexa-2,5-dienone;
(3)3-[(2'-hydroxyacetic acid)acetamide]-1,1-dimethyl-6-hydroxymethyl- 2-sulfhydryl-cyclohexa-2,5-dienone;
(4)3-[(2'-hydroxyacetic acid)methanamine]-1,1-dimethyl-6- hydroxymethyl-2-sulfhydryl-cyclohexa-2,5-dienone;
(5)3-[(2'-hydroxyacetic acid)ethanamine]-1,1-dimethyl-6- hydroxymethyl-2-sulfhydryl-cyclohexa-2,5-dienone;
(6)3-[(2'-hydroxyacetic acid)ethanamine]-1,1-dimethyl-6-[(β-D- glucopyranosyl)hydroxymethyl]-2-sulfhydryl-cyclohexa-2,5-dienone;
(7)2-β-D-glucopyranosyl-7-hydroxymethyl-8,8-dimethyl-4,8-dihydrobenzo [1,4]thiazine-3,5-dione;
(8)xanthiazone;
(9)xanthiside;
(10)2-Hydroxy-xanthiazone;
(11)2-Hydroxy-xanthiside。
Preferably, in the n-butanol component of 70% ethanol extract of the achene of Siberian cocklebur content of xanthiside account for it is described grey At least the 10% of the n-butanol component of 70% ethanol extract of the ears or side handles of a utensil, it is furthermore preferred that 70% ethanol extract of the achene of Siberian cocklebur The content of xanthiside accounts for the n-butanol component of 70% ethanol extract of the achene of Siberian cocklebur at least in n-butanol component 20%;Most preferably, in the n-butanol component of 70% ethanol extract of the achene of Siberian cocklebur content of xanthiside account for it is described grey At least the 30% of the n-butanol component of 70% ethanol extract of the ears or side handles of a utensil.
In another aspect, the present invention provides a kind of prevention and/or the pharmaceutical compositions for the treatment of rheumatism, rheumatoid arthritis Object, it is characterised in that the active constituent of described pharmaceutical composition is selected from the one or more of following compound:
(1)7-[(β-D-apiofuranosyl-(1→6)-β-D-glucopyranosyl)oxymethy]-8,8- dimethyl-4,8-dihydrobenzo[1,4]thiazine-3,5-dione;
(2)3-[(2'-hydroxyacetic acid)amino]-1,1-dimethyl-6-hydroxymethyl-2- sulfhydryl-cyclohexa-2,5-dienone;
(3)3-[(2'-hydroxyacetic acid)acetamide]-1,1-dimethyl-6-hydroxymethyl- 2-sulfhydryl-cyclohexa-2,5-dienone;
(4)3-[(2'-hydroxyacetic acid)methanamine]-1,1-dimethyl-6- hydroxymethyl-2-sulfhydryl-cyclohexa-2,5-dienone;
(5)3-[(2'-hydroxyacetic acid)ethanamine]-1,1-dimethyl-6- hydroxymethyl-2-sulfhydryl-cyclohexa-2,5-dienone;
(6)3-[(2'-hydroxyacetic acid)ethanamine]-1,1-dimethyl-6-[(β-D- glucopyranosyl)hydroxymethyl]-2-sulfhydryl-cyclohexa-2,5-dienone;
(7)2-β-D-glucopyranosyl-7-hydroxymethyl-8,8-dimethyl-4,8-dihydrobenzo [1,4]thiazine-3,5-dione;
(8)xanthiazone;
(9)xanthiside;
(10)2-Hydroxy-xanthiazone;
(11)2-Hydroxy-xanthiside。
Preferably, the active constituent of described pharmaceutical composition is selected from the one or more of following compound:
(1)7-[(β-D-apiofuranosyl-(1→6)-β-D-glucopyranosyl)oxymethy]-8,8- dimethyl-4,8-dihydrobenzo[1,4]thiazine-3,5-dione;
(3)3-[(2'-hydroxyacetic acid)acetamide]-1,1-dimethyl-6-hydroxymethyl- 2-sulfhydryl-cyclohexa-2,5-dienone;
(5)3-[(2'-hydroxyacetic acid)ethanamine]-1,1-dimethyl-6- hydroxymethyl-2-sulfhydryl-cyclohexa-2,5-dienone;
(8)xanthiazone;
(9)xanthiside。
It is furthermore preferred that the active constituent of described pharmaceutical composition is selected from or mixtures thereof xanthiazone, xanthiside
Most preferably, the active constituent of described pharmaceutical composition is xanthiside.
It is of the present invention to prevent and/or treat rheumatism, the dosage form of the pharmaceutical composition of rheumatoid arthritis selected from external application Topical formulations, gastrointestinal administration composition, parenteral administration composition.
Preferably, local external use's preparation is selected from:Plaster, cataplasm, ointment, cream, tincture, gelling agent, gas Mist agent, spray;The gastrointestinal administration composition is selected from:Tablet, capsule, granule, powder, solution etc.;The stomach Parenteral administration composition is selected from:Injection, freeze drying powder injection etc..
The content of active constituent accounts for the 5-80% of pharmaceutical composition total weight in pharmaceutical composition of the present invention, preferably , the content of active constituent accounts for the 10-60% of pharmaceutical composition total weight in described pharmaceutical composition, it is furthermore preferred that the medicine The content of active constituent accounts for the 15% of pharmaceutical composition total weight in compositions.
Another aspect, the present invention provides the ethyl acetate component of cocklebur fruit ethanol extract or n-butanol component or its Mixture is preparing prevention and/or treatment rheumatism, the purposes of the pharmaceutical composition of rheumatoid arthritis.
Preferably, the cocklebur fruit ethanol extract is achene of Siberian cocklebur 50-90% ethanol extracts, it is furthermore preferred that described grey Ears or side handles of a utensil ethanol extract is achene of Siberian cocklebur 60-80% ethanol extracts;The most preferred cocklebur fruit ethanol extract is the achene of Siberian cocklebur 70% ethanol extract.
Preferably, the present invention provides the n-butanol components of 70% ethanol extract of the achene of Siberian cocklebur prevents and/or controls preparing Treat rheumatism, the purposes of the pharmaceutical composition of rheumatoid arthritis.
Preferably, one kind or more of following compound is included in the n-butanol component of 70% ethanol extract of the achene of Siberian cocklebur Kind:
(1)7-[(β-D-apiofuranosyl-(1→6)-β-D-glucopyranosyl)oxymethy]-8,8- dimethyl-4,8-dihydrobenzo[1,4]thiazine-3,5-dione;
(2)3-[(2'-hydroxyacetic acid)amino]-1,1-dimethyl-6-hydroxymethyl-2- sulfhydryl-cyclohexa-2,5-dienone;
(3)3-[(2'-hydroxyacetic acid)acetamide]-1,1-dimethyl-6-hydroxymethyl- 2-sulfhydryl-cyclohexa-2,5-dienone;
(4)3-[(2'-hydroxyacetic acid)methanamine]-1,1-dimethyl-6- hydroxymethyl-2-sulfhydryl-cyclohexa-2,5-dienone;
(5)3-[(2'-hydroxyacetic acid)ethanamine]-1,1-dimethyl-6- hydroxymethyl-2-sulfhydryl-cyclohexa-2,5-dienone;
(6)3-[(2'-hydroxyacetic acid)ethanamine]-1,1-dimethyl-6-[(β-D- glucopyranosyl)hydroxymethyl]-2-sulfhydryl-cyclohexa-2,5-dienone;
(7)2-β-D-glucopyranosyl-7-hydroxymethyl-8,8-dimethyl-4,8-dihydrobenzo [1,4]thiazine-3,5-dione;
(8)xanthiazone;
(9)xanthiside;
(10)2-Hydroxy-xanthiazone;
(11)2-Hydroxy-xanthiside。
The content of xanthiside accounts for described in the n-butanol component of 70% ethanol extract of the preferred achene of Siberian cocklebur At least the 10% of the n-butanol component of 70% ethanol extract of the achene of Siberian cocklebur, it is furthermore preferred that 70% ethanol extract of the achene of Siberian cocklebur N-butanol component in the content of xanthiside account for the n-butanol component of 70% ethanol extract of the achene of Siberian cocklebur at least 20%;Most preferably, in the n-butanol component of 70% ethanol extract of the achene of Siberian cocklebur content of xanthiside account for it is described grey At least the 30% of the n-butanol component of 70% ethanol extract of the ears or side handles of a utensil.
On the other hand, the present invention also provides a kind of prevention and/or treatment rheumatism, the medicine groups of rheumatoid arthritis Close the preparation method of object comprising following steps:
(1) it stocks up:The achene of Siberian cocklebur is weighed, is crushed, 10-30 mesh sieve is crossed, obtains Siberian Cocklebur Fruit;
(2) preparation of cocklebur fruit ethanol extract:Siberian Cocklebur Fruit obtained by step (1) is added 5-10 times and measures 50-90% Ethyl alcohol extracts 1-3h using heat reflow method, and dry cream is obtained after being concentrated after filtered fluid recycling ethyl alcohol after filtering;
(3) it extracts:Step (2) is got dry extract and is extracted successively using petroleum ether, ethyl acetate, n-butanol respectively, And obtain opposed polarity position, i.e. petroleum ether component (petroleum ether, PE), ethyl acetate component (ethyl Acetate, EA), n-butanol component (n-Butyl alcohol, BA) and water layer component (water), select ethyl acetate group Point, or mixtures thereof n-butanol component, add manufacturing cost invention after pharmaceutically acceptable auxiliary material and prevent and/or treatment wind Wet, rheumatoid arthritis pharmaceutical composition.
Preferably, the achene of Siberian cocklebur is weighed in step (1), crushed, cross 20 mesh sieve;Step (2) is by the achene of Siberian cocklebur obtained by step (1) Powder adds 8 times of 70% ethyl alcohol of amount, and 2h is extracted using heat reflow method, is done after being concentrated after filtered fluid recycling ethyl alcohol after filtering Cream.
Beneficial effects of the present invention:
The present invention, which screens to have obtained in the achene of Siberian cocklebur to have in ethanol extract, prevents and/or treats rheumatism, rheumatoid pass Scorching active component, wherein the ethyl acetate component, n-butanol component of achene of Siberian cocklebur 50-90% ethanol extracts are saved, is had notable Rheumatism, the therapeutic effect of rheumatoid arthritis, can obviously inhibit TNF-α induce RAFLS cells proliferation, hence it is evident that subtract The redness and swelling of joints situation of light RA rat models, reduces RA rat arthritis indexes, it is obviously good that RA rat articular synovial membranes thicken situation Turn, inflammatory cell infiltration is reduced in synovium of joint, and it is scorching can effectively to reduce TNF-α in RA rat blood serums, PGE2 and IL-1 β etc. The content of property molecule.
The present invention also further isolates and purifies the n-butanol component of achene of Siberian cocklebur 50-90% ethanol extracts, obtains To 11 particular compounds, which shows the RAFLS cells of excellent inhibition TNF-α induction The effect of proliferation, wherein it is especially the most apparent with xanthiside effects, it can be used for the prevention of rheumatism, rheumatoid arthritis With treatment.
Description of the drawings
Attached drawing 1:Influence of the achene of Siberian cocklebur opposed polarity position to rat toes swelling;
Attached drawing 2:Influence of the achene of Siberian cocklebur opposed polarity position to RA rat arthritis indexes;
Attached drawing 3:Influence of the achene of Siberian cocklebur opposed polarity position to RA rat articular synovial membranes;
Attached drawing 4:Influence of the achene of Siberian cocklebur opposed polarity position to RA rat blood serum TNF-α;
Attached drawing 5:Influence of the achene of Siberian cocklebur opposed polarity position to RA rat blood serum IL-1 β;
Attached drawing 6:Influence of the achene of Siberian cocklebur opposed polarity position to RA rat blood serums PEG2.
Specific implementation mode
Following embodiment is intended to illustrate invention rather than the present invention further limits, and the present invention can be by invention content The either type is implemented.
Embodiment 1:A kind of tablet prevented and/or treat rheumatism, rheumatoid arthritis
It prepares according to the following steps:
(1) it stocks up:The achene of Siberian cocklebur is weighed, is crushed, 20 mesh sieve is crossed, obtains Siberian Cocklebur Fruit;
(2) preparation of cocklebur fruit ethanol extract:Siberian Cocklebur Fruit obtained by step (1) is added into 8 times of 70% ethyl alcohol of amount, is made 2h is extracted with heat reflow method, dry cream is obtained after being concentrated after filtered fluid recycling ethyl alcohol after filtering;
(3) it extracts:Step (2) is got dry extract and is extracted successively using petroleum ether, ethyl acetate, n-butanol respectively, And obtain opposed polarity position, i.e. petroleum ether component (petroleum ether, PE), ethyl acetate component (ethyl Acetate, EA), n-butanol component (n-Butyl alcohol, BA) and water layer component (water), select n-butanol component, The invention of tabletting manufacturing cost prevents and/or treats the piece of rheumatism, rheumatoid arthritis after adding pharmaceutically acceptable auxiliary material Agent.
Embodiment 2:A kind of capsule prevented and/or treat rheumatism, rheumatoid arthritis
It prepares according to the following steps:
(1) it stocks up:The achene of Siberian cocklebur is weighed, is crushed, 20 mesh sieve is crossed, obtains Siberian Cocklebur Fruit;
(2) preparation of cocklebur fruit ethanol extract:Siberian Cocklebur Fruit obtained by step (1) is added into 8 times of 70% ethyl alcohol of amount, is made 2h is extracted with heat reflow method, dry cream is obtained after being concentrated after filtered fluid recycling ethyl alcohol after filtering;
(3) it extracts:Step (2) is got dry extract and is extracted successively using petroleum ether, ethyl acetate, n-butanol respectively, And obtain opposed polarity position, i.e. petroleum ether component (petroleum ether, PE), ethyl acetate component (ethyl Acetate, EA), n-butanol component (n-Butyl alcohol, BA) and water layer component (water), select ethyl acetate component With n-butanol component, add filling after pharmaceutically acceptable auxiliary material prevent to manufacturing cost invention after gelatine capsule shell and/or Treat the capsule of rheumatism, rheumatoid arthritis.
Embodiment 3:A kind of granule prevented and/or treat rheumatism, rheumatoid arthritis
It prepares according to the following steps:
(1) it stocks up:The achene of Siberian cocklebur is weighed, is crushed, 20 mesh sieve is crossed, obtains Siberian Cocklebur Fruit;
(2) preparation of cocklebur fruit ethanol extract:Siberian Cocklebur Fruit obtained by step (1) is added into 8 times of 70% ethyl alcohol of amount, is made 2h is extracted with heat reflow method, dry cream is obtained after being concentrated after filtered fluid recycling ethyl alcohol after filtering;
(3) it extracts:Step (2) is got dry extract and is extracted successively using petroleum ether, ethyl acetate, n-butanol respectively, And obtain opposed polarity position, i.e. petroleum ether component (petroleum ether, PE), ethyl acetate component (ethyl Acetate, EA), n-butanol component (n-Butyl alcohol, BA) and water layer component (water), select ethyl acetate group Point, add of manufacturing cost invention prevention and/or treatment rheumatism, rheumatoid arthritis after pharmaceutically acceptable auxiliary material Granula.
Effect example 1:The inhibited proliferation for the RAFLS cells that achene of Siberian cocklebur opposed polarity position induces TNF-α
1.1 experimental drug
The petroleum ether component (petroleum ether, PE) of the 1 gained achene of Siberian cocklebur of embodiment, 70% ethanol extract, acetic acid Components (ethyl acetate, EA), n-butanol component (n-Butyl alcohol, BA) and water layer component (water), Compound:
(1)7-[(β-D-apiofuranosyl-(1→6)-β-D-glucopyranosyl)oxymethy]-8,8- dimethyl-4,8-dihydrobenzo[1,4]thiazine-3,5-dione
(2)3-[(2'-hydroxyacetic acid)amino]-1,1-dimethyl-6-hydroxymethyl-2- sulfhydryl-cyclohexa-2,5-dienone
(3)3-[(2'-hydroxyacetic acid)acetamide]-1,1-dimethyl-6-hydroxymethyl- 2-sulfhydryl-cyclohexa-2,5-dienone
(4)3-[(2'-hydroxyacetic acid)methanamine]-1,1-dimethyl-6- hydroxymethyl-2-sulfhydryl-cyclohexa-2,5-dienone
(5)3-[(2'-hydroxyacetic acid)ethanamine]-1,1-dimethyl-6- hydroxymethyl-2-sulfhydryl-cyclohexa-2,5-dienone
(6)3-[(2'-hydroxyacetic acid)ethanamine]-1,1-dimethyl-6-[(β-D- glucopyranosyl)hydroxymethyl]-2-sulfhydryl-cyclohexa-2,5-dienone
(7)2-β-D-glucopyranosyl-7-hydroxymethyl-8,8-dimethyl-4,8-dihydrobenzo [1,4]thiazine-3,5-dione
(8)xanthiazone
(9)xanthiside
(10)2-Hydroxy-xanthiazone
(11)2-Hydroxy-xanthiside
1.2 experimental method
The RAFLS cell models of TNF-α induction are established, wherein RAFLS cells use tissue mass cell culture, and rheumatoid is closed The scorching patient's synovial membrane of section shreds under aseptic condition, digests 4h in 37 DEG C using the collagenase type I (Gibco BRL) of 1.0mg/mL, Cell is collected by centrifugation, 20%FBS DMEM (Gibco BRL) culture solution is added, is placed in 37 DEG C, 5%CO2It is cultivated to thin in incubator Intracellular growth is to had digestive transfer culture when 85%.
By the petroleum ether component of 70% ethanol extract of the achene of Siberian cocklebur, ethyl acetate component, n-butanol component and water layer component And 11 compounds are formulated as being added to the RAFLS cells of TNF-α induction after gradient concentration, continue after cultivating 48h, detection is each The growth inhibition effect for the RAFLS cells that component and compound induce TNF-α calculates what each component induced TNF-α The half-inhibition concentration (IC50) of RAFLS cells, specific experiment the results are shown in Table 1.
1.3 data processing
Experimental data using 19.0 statistical softwares of SPSS it is for statistical analysis, each group of data withIt indicates.Institute's total According to making t inspections, P after making homogeneity of variance experiment<0.05 is statistically significant.
1.4 experimental result
The inhibited proliferation for the RAFLS cells that 1 achene of Siberian cocklebur opposed polarity position of table induces TNF-α
1 experimental result of table shows the petroleum ether component of 70% ethanol extract of the achene of Siberian cocklebur, ethyl acetate component, n-butanol group Point, water layer component and 11 particular compounds show certain inhibition to RAFLS cell Proliferations, wherein positive fourth The RAFLS cyto-inhibitions that the specific compound of alkoxide component, ethyl acetate component and 11 induces TNF-α are more notable, And the inhibition conduct for the RAFLS cells that n-butanol component induces TNF-α in extract is the most notable, and 11 specific chemical combination The inhibition conduct for the RAFLS cells that compound 9 (xanthiside) induces TNF-α in object is the most notable.
Effect example 2:Internal anti-RA activity research of the achene of Siberian cocklebur opposed polarity position to RA rats
2.1 experimental drug
The petroleum ether component (petroleum ether, PE) of the 1 gained achene of Siberian cocklebur of embodiment, 70% ethanol extract, acetic acid Components (ethyl acetate, EA), n-butanol component (n-Butyl alcohol, BA) and water layer component (water), Using normal saline at 0.25%, 0.5% and 1% basic, normal, high dose suspension, dexamethasone use physiological saline It is configured to 0.1% solution, it is spare.
II collagen types are dissolved in 0.1% acetum, are configured to the solution of a concentration of 2mg/mL, in 4 DEG C of ice Case is stood overnight.Experiment mixes II collagen types acetum with the Freund's complete adjuvant of equivalent 2mg/mL before starting, Under condition of ice bath by its it is homogeneous turn to emulsion, it is spare.
2.2 experimental method
Male SD rat 75, weight 180-220g, is randomly divided into 15 groups, every group 5, specially:Blank group, model Group, positive drug group, basic, normal, high group of petroleum ether component, basic, normal, high group of ethyl acetate component, basic, normal, high group of n-butanol component With basic, normal, high group of water layer component.After all rat adaptability raising 1d, blank group rat is in Rat Right metapedes bottom, root of the tail portion With 3 points of hypodermic injection physiological saline 0.25mL of back portion, model group, positive drug group, petroleum ether group, ethyl acetate group, positive fourth Alcohol group and water layer group rat in 3 points of Rat Right metapedes bottom, root of the tail portion and back portion be subcutaneously injected comprising II collagen types with The emulsion 0.25mL of Freund's complete adjuvant, each group rat repeats that physiological saline is subcutaneously injected or includes II collagen types after 7 days With the emulsion 0.25mL of Freund's complete adjuvant.
After second is subcutaneously injected 1d, blank group rat is normally raised, every rat oral gavage 2mL physiological saline of model group, Positive drug group gavage dexamethasone solution 2mL, the relative medicine suspension of other each group gavages 2mL, successive administration 21d, with 8d after primary immunization, 14d, it is within the 21st, the 28th day reference index, records the arthritis index of each group rat;Last dose Each group rat immunity position shape metamorphosis is observed after 1h;Rat eye socket takes blood after last dose 2h, is surveyed using ELISA method Determine TNF-α in each group rat blood serum, the content of PGE2 and IL-1 β;Rat is put to death using cervical dislocation after eye socket takes blood, is taken Left back ankle joint, is put into 10% neutral formalin solution and fixes 2d, reuses 8% formic acid decalcification 14d, stone after dehydration Wax embeds, slice, after HE dyeing, observes synovial tissue's pathological change, specific experiment the result is shown in Figure 1-4.
2.3 data processing
Experimental data using 19.0 statistical softwares of SPSS it is for statistical analysis, each group of data withIt indicates.Institute's total According to making t inspections, P after making homogeneity of variance experiment<0.05 is statistically significant.
2.4 experimental result
(1) the observation result that achene of Siberian cocklebur opposed polarity position changes RA rat immunities position mode of appearance
There is the red and swollen phenomenon in joint in model group and administration each group rat after immune.Compared with blank group, model group Rat toes redness and swelling of joints is apparent, includes the redness of small articulations digitorum manus, the redness in entire toe face, while rat is slow in action;With Model group is compared, and positive drug dexamethasone is substantially reduced rat articular redness phenomenon;The high, medium and low dosage group rat of n-butanol is closed The red and swollen situation of section gradually mitigates, and is reduced with dosage, acts on and gradually weakening.The high dose component of water layer and ethyl acetate layer also may be used Partly to mitigate rat articular redness phenomenon, but function and effect are markedly less than n-butanol component, and petroleum ether group is grouped rat in reality It is red and swollen apparent to test the entire toe position of process rat, and does not show the sign being relieved in whole experiment process, shows The petroleum ether extraction component of cocklebur fruit ethanol extract alleviates the redness and swelling of joints of rheumatism, rheumatoid arthritis rat Effect is weaker (as shown in Fig. 1).
(2) observation result of the achene of Siberian cocklebur opposed polarity position to RA rat arthritis index (AI)
After modeling, since the 5th day, each modeling group rat immunity joint started red and swollen phenomenon occur, the about the 8th day each group There is apparent red and swollen phenomenon in rat immunity joint.Experimental result shows that the high, medium and low dosage group of n-butanol was since the 8th day AI is integrated and the significant difference (P of model group<0.05), and over time, difference becomes larger, and conspicuousness also increases Greatly, illustrate that n-butanol component can obviously inhibit the redness and swelling of joints of rat.The AI integrals of positive drug Dexamethasone group rat are apparent low In model group, there is pole significant difference (P<0.01).Compared with model group, water layer high dose group and ethyl acetate high dose Group had significant difference (P since 14 days<0.05).And in water layer and ethyl acetate layer, low dose group and petroleum ether The each dosage group of layer is contrasted with model group, difference that there are no significant (as shown in Figure 2).
(3) pathological observation of the achene of Siberian cocklebur opposed polarity position to RA rat articulars
Compared with model group, water layer component and ethyl acetate component intrasynovial cell arrangement are irregular, there is concave-convex phenomenon, sliding Film thicken situation have it is a little take a turn for the better, in synovium of joint inflammatory cell infiltration reduce.And petroleum ether component is then to joint tissue, pass The lesions of synovium contributed is saved almost without effect.N-butanol component and positive drug group intrasynovial cell arrangement slightly restore neatly, clearly may be used See, synovial membrane thickens situation and obviously takes a turn for the better, and inflammatory cell infiltration is reduced in synovium of joint.Illustrate achene of Siberian cocklebur n-butanol component to class Rheumatoid arthritis disease change improves significantly (as shown in Figure 3).
(4) influence of the achene of Siberian cocklebur opposed polarity position to inflammatory factor in RA rat blood serums
Experimental result shows, in model group rats serum TNF-α, PGE2 and IL-1 β contents obviously higher than blank group, and Positive drug dexamethasone significantly reduces TNF-α in model group rats serum, the content of PGE2 and IL-1 β, 70% second of the achene of Siberian cocklebur Petroleum ether component, ethyl acetate component, n-butanol component and the water layer component of alcohol extracting thing show certain reduction RA rats TNF-α, the effect of PGE2 and IL-1 β contents in serum, it is shown that certain antiphlogistic effects, wherein n-butanol component effect are most To be apparent, and with significant difference compared with model group, the n-butanol group to show cocklebur fruit ethanol extract is divided into The active component (as Figure 4-Figure 6) of the anti-RA of the achene of Siberian cocklebur.
Above example is only enumerating for the present invention, is prevented with Chinese medicine composition of the present invention and/or treatment polycystic ovary is comprehensive The technical solution of simulator sickness and its relevant disease is each fallen in protection scope of the present invention.

Claims (10)

1. a kind of prevention and/or treatment rheumatism, the pharmaceutical composition of rheumatoid arthritis, it is characterised in that the pharmaceutical composition Object is with or mixtures thereof the ethyl acetate component of cocklebur fruit ethanol extract or n-butanol component for active constituent.
2. prevention according to claim 1 and/or treatment rheumatism, the pharmaceutical composition of rheumatoid arthritis, feature It is that the cocklebur fruit ethanol extract is achene of Siberian cocklebur 50-90% ethanol extracts.
3. prevention according to claim 2 and/or treatment rheumatism, the pharmaceutical composition of rheumatoid arthritis, feature It is that the cocklebur fruit ethanol extract is achene of Siberian cocklebur 60-80% ethanol extracts.
4. prevention according to claim 3 and/or treatment rheumatism, the pharmaceutical composition of rheumatoid arthritis, feature It is that the cocklebur fruit ethanol extract is 70% ethanol extract of the achene of Siberian cocklebur.
5. prevention according to claim 4 and/or treatment rheumatism, the pharmaceutical composition of rheumatoid arthritis, feature It is that the n-butanol group with 70% ethanol extract of the achene of Siberian cocklebur is divided into active constituent, 70% ethanol extract of the achene of Siberian cocklebur is just Comprising one or more in following compound in butanol component:
(1)7-[(β-D-apiofuranosyl-(1→6)-β-D-glucopyranosyl)oxymethy]-8,8- dimethyl-4,8-dihydrobenzo[1,4]thiazine-3,5-dione;
(2)3-[(2'-hydroxyacetic acid)amino]-1,1-dimethyl-6-hydroxymethyl-2- sulfhydryl-cyclohexa-2,5-dienone;
(3)3-[(2'-hydroxyacetic acid)acetamide]-1,1-dimethyl-6-hydroxymethyl-2- sulfhydryl-cyclohexa-2,5-dienone;
(4)3-[(2'-hydroxyacetic acid)methanamine]-1,1-dimethyl-6-hydroxymethyl-2- sulfhydryl-cyclohexa-2,5-dienone;
(5)3-[(2'-hydroxyacetic acid)ethanamine]-1,1-dimethyl-6-hydroxymethyl-2- sulfhydryl-cyclohexa-2,5-dienone;
(6)3-[(2'-hydroxyacetic acid)ethanamine]-1,1-dimethyl-6-[(β-D- glucopyranosyl)hydroxymethyl]-2-sulfhydryl-cyclohexa-2,5-dienone;
(7)2-β-D-glucopyranosyl-7-hydroxymethyl-8,8-dimethyl-4,8-dihydrobenzo[1, 4]thiazine-3,5-dione;
(8)xanthiazone;
(9)xanthiside;
(10)2-Hydroxy-xanthiazone;
(11)2-Hydroxy-xanthiside。
6. prevention according to claim 5 and/or treatment rheumatism, the pharmaceutical composition of rheumatoid arthritis, feature It is that the content of xanthiside in the n-butanol component of 70% ethanol extract of the achene of Siberian cocklebur accounts for 70% second of the achene of Siberian cocklebur At least the 10% of the n-butanol component of alcohol extracting thing.
7. preventing and/or treating the pharmaceutical composition of rheumatism, rheumatoid arthritis according to claim 1-6 any one of them Object, it is characterised in that the dosage form of described pharmaceutical composition is selected from local external use's preparation, gastrointestinal administration composition, parenteral gives Drug composition.
8. prevention according to claim 7 and/or treatment rheumatism, the pharmaceutical composition of rheumatoid arthritis, feature It is that local external use's preparation is selected from:Plaster, cataplasm, ointment, cream, tincture, gelling agent, aerosol, spray; The gastrointestinal administration composition is selected from:Tablet, capsule, granule, powder, solution;The parenteral administration combination Object is selected from:Injection, freeze drying powder injection.
9. or mixtures thereof ethyl acetate component or n-butanol component of cocklebur fruit ethanol extract are prevented and/or are treated preparing The purposes of rheumatism, the pharmaceutical composition of rheumatoid arthritis.
10. claim 1-9 any one of them is prevented and/or treatment rheumatism, the pharmaceutical composition of rheumatoid arthritis Preparation method, it is characterised in that include the following steps:
(1) it stocks up:The achene of Siberian cocklebur is weighed, is crushed, 10-30 mesh sieve is crossed, obtains Siberian Cocklebur Fruit;
(2) preparation of cocklebur fruit ethanol extract:Siberian Cocklebur Fruit obtained by step (1) is added 5-10 times and measures 50-90% ethyl alcohol, 1-3h is extracted using heat reflow method, dry cream is obtained after being concentrated after filtered fluid recycling ethyl alcohol after filtering;
(3) it extracts:Step (2) is got dry extract and is extracted successively using petroleum ether, ethyl acetate, n-butanol respectively, and is obtained Opposed polarity position, i.e., petroleum ether component (petroleum ether, PE), ethyl acetate component (ethyl acetate, EA), n-butanol component (n-Butyl alcohol, BA) and water layer component (water) select ethyl acetate component, n-butanol group Or mixtures thereof point, it adds and is prepared into prevention after pharmaceutically acceptable auxiliary material and/or treats rheumatism, rheumatoid arthritis Pharmaceutical composition.
CN201810458324.8A 2018-05-14 2018-05-14 The preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur Pending CN108514568A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810458324.8A CN108514568A (en) 2018-05-14 2018-05-14 The preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810458324.8A CN108514568A (en) 2018-05-14 2018-05-14 The preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur

Publications (1)

Publication Number Publication Date
CN108514568A true CN108514568A (en) 2018-09-11

Family

ID=63430645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810458324.8A Pending CN108514568A (en) 2018-05-14 2018-05-14 The preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur

Country Status (1)

Country Link
CN (1) CN108514568A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109498625A (en) * 2018-12-29 2019-03-22 温州医科大学附属第医院 A kind of pharmaceutical composition and preparation method thereof for treating Chronic Obstructive Pulmonary Disease
CN110038023A (en) * 2019-04-19 2019-07-23 温州医科大学 A kind of pharmaceutical composition for the antiallergic activity substituting the achene of Siberian cocklebur

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1994352A (en) * 2005-03-28 2007-07-11 中国人民解放军第二军医大学 Use of total glucosides extract of cocklebur fruit in preparation of product for resisting inflammatory reaction
CN108283643A (en) * 2017-12-25 2018-07-17 中国人民解放军第二军医大学 A kind of thiazadione class compound prepare prevent or the drug for the treatment of rheumatoid arthritis in application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1994352A (en) * 2005-03-28 2007-07-11 中国人民解放军第二军医大学 Use of total glucosides extract of cocklebur fruit in preparation of product for resisting inflammatory reaction
CN108283643A (en) * 2017-12-25 2018-07-17 中国人民解放军第二军医大学 A kind of thiazadione class compound prepare prevent or the drug for the treatment of rheumatoid arthritis in application

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BING LIN等: "Anti-arthritic activity of Xanthium strumarium L. extract on complete Freund"s adjuvant induced arthritis in rats", 《JOURNAL OF ETHNOPHARMACOLOGY》 *
HAI JIANG等: "Four New Glycosides from the Fruit of Xanthium sibiricum Patr.", 《MOLECULES》 *
RONG-HUA YIN等: "Two new compounds from Xanthium strumarium", 《JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH》 *
T.HAN等: "Bioactivity-guided fractionation for anti-inflammatory and analgesic properties and constituents of Xanthium strumarium L", 《PHYTOMEDICINE》 *
刘道清: "《百病自诊自疗自防》", 31 December 1999, 四川辞书出版社 *
吴凌凤等: "苍耳子的化学成分与质量控制研究进展 ", 《内蒙古中医药》 *
孙延萍: "苍耳子抗炎活性部位的筛选", 《今日科苑》 *
崔秀荣等: "苍耳子的化学成分和临床应用研究进展", 《现代药物与临床》 *
庄延双等: "苍耳子化学成分及药理作用研究进展 ", 《南京中医药大学学报》 *
秦路平: "中药民族药抗类风湿关节炎活性物质基础及作用机制研究", 《第八届中国民族植物学学术研讨会暨第七届亚太民族植物学论坛》 *
邱玉玲等: "HPLC法测定苍耳子中苍耳子噻嗪双酮苷的含量 ", 《沈阳药科大学学报》 *
韩婷: "苍耳子活性部位中抗炎镇痛化学成分的研究", 《中华中医药学会第九届中药鉴定学术会议论文集》 *
马金忠: "《骨关节病》", 30 April 2009 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109498625A (en) * 2018-12-29 2019-03-22 温州医科大学附属第医院 A kind of pharmaceutical composition and preparation method thereof for treating Chronic Obstructive Pulmonary Disease
CN109498625B (en) * 2018-12-29 2021-04-16 温州医科大学附属第一医院 Pharmaceutical composition for treating chronic obstructive pulmonary disease and preparation method thereof
CN110038023A (en) * 2019-04-19 2019-07-23 温州医科大学 A kind of pharmaceutical composition for the antiallergic activity substituting the achene of Siberian cocklebur
CN110038023B (en) * 2019-04-19 2021-05-07 温州医科大学 Anti-allergic pharmaceutical composition for replacing cocklebur fruit

Similar Documents

Publication Publication Date Title
CN104667044A (en) Traditional Chinese medicine preparation for treating arthralgia and preparation method of traditional Chinese medicine preparation
CN108514568A (en) The preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur
CN108853433A (en) A kind of Chinese medicine and preparation method thereof for treating diabetic nephropathy
CN103405582A (en) Traditional Chinese medicine composition for improving joint gall of rheumatoid arthritis
CN101584810B (en) Medicine composition for treating gastritis and peptic ulcer and preparation method thereof
CN101112533A (en) A Chinese medicinal composition for treating and preventing gout, and its preparation method
CN103977390B (en) A kind of preparation method and its usage of ginger onion medicated wine composition
CN102670977A (en) Chinese medicinal composition for treating arthralgia, preparation method and applications of Chinese medicinal composition
JP7340113B2 (en) Chinese herbal composition and its production method and use
CN103977106A (en) Traditional Chinese medicine preparation for treating nephrotic syndrome and preparation method thereof
CN103142841A (en) Traditional Chinese medicine composition for treating osteonecrosis of femoral head
CN103705772B (en) Chinese medicine composition that a kind of antiinflammatory protects the liver and preparation method thereof
CN105477465A (en) Chinese herb preparation with liver protection function and preparing technology of Chinese herb preparation
CN108743885A (en) A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications
CN102274428A (en) Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof
CN108403906A (en) A kind of pharmaceutical composition and preparation method thereof of prevention rheumatoid arthritis
CN108704080B (en) Medicine for treating kidney yin deficiency type depression and preparation method thereof
CN106474297A (en) Improve pharmaceutical composition of gerontal patient&#39;s postoperative cognition disorders and preparation method thereof
CN106177250A (en) A kind of Chinese medicine composition treating chronic nephritis
CN106236971A (en) A kind of Chinese medicine composition treating chronic nephritis
CN106237014A (en) A kind of Chinese medicine composition treating chronic nephritis
CN106138637A (en) A kind of Chinese medicine composition of blood circulation promoting and blood stasis dispelling rheumatism pain relieving and preparation method thereof
CN1907315A (en) Orthopaedics disease treating and preventing medicinal composition
CN105435018A (en) Traditional Chinese medicine preparation for treating gout and preparation method thereof
CN103156940B (en) A kind of extracting technique of Chinese medicine for garden balsam stem pain-relieving

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180911

RJ01 Rejection of invention patent application after publication